CMA says MSD operated anti-competitive Remicade scheme
The UK Competition and Markets Authority (CMA) has provisionally decided that Merck Sharp & Dohme operated an anti-competitive discount scheme for its drug Remicade (infliximab).
Remicade is a biological treatment for patients with gastroenterology and rheumatology conditions.
In a statement released yesterday, the CMA said it had provisionally found that Merck broke competition law.
CMA said that Merck did this through a discount scheme for Remicade that was “likely to restrict competition” for biosimilar versions of infliximab.
It added: “At this stage of the CMA’s investigation, these findings are provisional and no conclusion should be drawn that there has in fact been any breach of competition law.
“The CMA will carefully consider any representations by the company under investigation before determining whether the law has been infringed.”
The CMA started this investigation in December 2015.
Today's stories
University of Maryland patent immune to IPR: PTAB
WIPO reveals new plan to fight tropical diseases
Federal Circuit rules in Mylan’s favour
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk